You are here: Industry Insights > VolitionRx

News List

Terumo Blood and Cell Technologies and PhotonPharma Inc. announce collaboration to develop a novel cancer immunotherapy prnasia
August 12, 2021
Terumo and PhotonPharma today announced they have established a memorandum of understanding (MOU) for collaboration to develop Innocell™, a novel tumor specific immunotherapy (a therapeutic vaccine) for solid tumors.
VolitionRx Completes Acquisition of Octamer GmbH prnasia
January 11, 2020
Volition also announced the receipt of additional non-dilutive funding in the form of a $550,000 (Euro 500,000) unsecured loan from Namur Invest to assist with the Octamer acquisition.
VolitionRx Limited Announces Third Quarter 2019 Financial Results and Business Update En-CPhI.CN
November 14, 2019
VolitionRx Limited announced financial results and a business update for the third quarter ended September 30, 2019.
VolitionRx commences lung cancer clinical study with Fosun in China biospectrumasia
July 22, 2019
Belgium based VolitionRx Limited has executed a contract under the previously announced Memorandum of Understanding, with Shanghai Fosun Long March Medical Science Co., Ltd. to help introduce the Nu.Q(TM) platform to China.
VolitionRx extends clinical trial programme in lung cancer biospectrumasia
April 08, 2019
VolitionRx Limited has announced that it has added to its extensive clinical trial program with the execution of ……
VolitionRx Announces Pricing of $8.4 Million Public Offering of Common Stock prnasia
March 12, 2018
VolitionRx Limited announced today the pricing of its previously announced underwritten public offering of 3,500,000 shares of common stock at a public offering price of $2.40 per share.
VolitionRx Announces Proposed Underwritten Public Offering of Common Stock prnasia
March 12, 2018
VolitionRx Limited announced today that it intends to offer and sell shares of its common stock in an underwritten public offering.
VolitionRx Appoints Harvard Professor, Dr. Lee-Jen Wei to Its Scientific Advisory Board prnasia
March 08, 2018
VolitionRx Limited today announced that it has further strengthened its Scientific Advisory Board with the addition of Dr. Lee-Jen Wei, a professor of Biostatistics at Harvard University.
VolitionRx Limited Announces Third Quarter 2017 Financial Results and Business Update prnasia
November 10, 2017
VolitionRx Limited (NYSE American: VNRX) today announced financial results and a business update for the third quarter ended September 30, 2017.
VolitionRx Limited Corrects an Earlier Announcement en-cphi.cn
June 28, 2017
VolitionRx Limited (NYSE MKT: VNRX) today has issued corrections to certain statements made in the press release issued by the Company on May 9, 2017 regarding the Company's Nu.Q™ Colorectal Cancer Screening Triage Test.